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Abstract
Background: Aim of the study was to assess predictors of discontinuation/toxicity of boosted PI-based (PI/r) dual
therapy (DT).
Methods: Observational, retrospective switch study in patients successfully treated with triple drugs regimen.
Patients switched to PI/r based DT [darunavir (DRV/r), lopinavir (LPV/r) or atazanavir (ATV/r)] plus a second drug:
[raltegravir (RAL), maraviroc (MVC) etravirine (ETR), lamivudine (3TC) or tenofovir (TDF)] between 2009 and
2014 were included. The effect of each drug as well as other clinical and virological cofactors over treatment
discontinuation (TD) was assessed using survival analysis.
Results: Overall, 376 patients were included with mean follow-up of 73 weeks. The most commonly used drugs
in DT were DRV/r (63.0 %) and RAL (53.7 %). TD was observed in 77 (20,4 %) patients: 38 (10,1 %) virological failure,
35 (9,3 %) toxicity/intolerance (4 deaths) and 4 (1 %) interruptions for patients decision. At Cox Model, adjusted
by demographic and laboratory variables, DRV/r and ATV/r significantly reduced the likelihood of TD and longer
treatment was associated with lower risk, while low CD4 count at baseline and number of previous regimens with
a higher risk. Moreover, RAL and 3TC use were significantly associated with lower TD by toxicity.
Conclusions: In our clinical practice experience, switching virologically suppressed patients to PI/r based DT
showed adequate safety and efficacy, so that it may be used in selected patients with specific medical needs.
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Background
The current standard combination antiretroviral therapy
(cART) for HIV-1 infection restores the immune func-
tion by limiting the progression of the disease [1]. The
introduction of cART in clinical practice significantly re-
duced HIV-related morbidity and mortality, improving
the quality of life (QoL) of people infected with HIV [2].
An Italian National Cohort study showed that toxicity is
the most frequent cause of discontinuation of cART [3].
In order to improve tolerance to new regimens as well
as to increase adherence and durability of treatments,
different strategies of simplification were investigated.
Simplification of cART regimens and improved patient
QoL today must also respond to cost/effectiveness cri-
teria, making them affordable for local health systems.
The simplification strategies may include drug dose re-
duction and daily administration reduction (up to single
tablet regimen, STR) or decrease in the number of anti-
retroviral drugs at time also defined as less drug regimen
or LDR [4].
In particular, LDR strategies consist of dual therapy
(DT) and mono-therapy (MT); in this setting, the most
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studied regimens include boosted protease inhibitors
(PI/r) due to the high genetic barrier of this drug class.
To date, the most relevant trials in the field are MT
studies evaluating the role of boosted darunavir (DRV/r)
MT [5, 6]. Both MT and DT strategies show generally
disappointing results in naïve patients [7–12] with few
exceptions for DT [11, 13], while encouraging results
have been observed switching to DT or MT in patients
with virological control of HIV infection both in clinical
studies and real life setting [5, 6, 13–19].
Moreover, PI/r use in DT or MT regimens is
associated to minimal or absent selection of drug-
resistant HIV variants [20, 21]. LDR also offers the
advantage of reduced toxicity associated with the use
of nucleoside reverse transcriptase inhibitors (NRTI).
Current literature provides adequate data from ran-
domized clinical trials regarding the safety and effi-
cacy of PI/r based DT in naïve patients [8–12, 22].
Recently, the first results from randomized clinical
trials regarding DT in treatment simplification were
presented [13, 14].
More data are required in order to better understand
the real utility of simplification strategies and in particu-
lar of DT regimens in clinical practice. Thus, we aimed
at assessing the durability of different DT regimens as
cART simplification, in terms of treatment discontinu-
ation or failure, and to evaluate the possible association
of the different drug combinations to the outcome.
Methods
Study design and patients included
This is an observational and retrospective study from
six Italian HIV reference centers enrolling patients on
virologically effective HAART who, between 2009 and
2014, underwent DT regimen including PI/r and a
second agent, according to clinician’s choice. Boosted
PI were DRV/r, lopinavir (LPV/r) or atazanavir (ATV/
r) and second agents were raltegravir (RAL), mara-
viroc (MVC), etravirine (ETR), lamivudine (3TC) or
tenofovir (TDF). Patients were included if on success-
ful HAART (HIV-RNA <50 copies/ml), no history of
PI failure and no primary resistance mutations to PI
or to second agents. Data were collected by investiga-
tors looking at any reason for starting DT regimen
and in particular patients were enrolled if patients
complained toxicity.
All patients of all the centers involved signed an in-
formed consent for use of their clinical and laboratory
data in aggregated and anonymous form and are aware
that the databases can be used to produce observational
studies. The procedure of collecting data was notified to
the ethic committees of the centers. Since the study was
performed within the data collected in the databases, no
specific ethical committee approval was needed.
Follow-up analysis
The follow-up was carried out up to DT discontinuation
or to the last observation available if patients did not
interrupted DT. During follow-up, virological and im-
munological data were recorded.
For patients who interrupted the treatment, date and
reason of discontinuation were also recorded. Patients
lost to follow-up, if in DT, were censored at the last
follow-up visit. Discontinuation for cause as secondary
endpoints (virological failure, toxicity or low adherence/
patient’ decision) were also analyzed individually. Viro-
logical failure was defined as two consecutive detectable
HIV-RNA (>50 copies/ml) or one detectable HIV-RNA
at the last visit. Patients with two consecutive detectable
HIV-RNA were considered as virological failure even if
they continued DT.
In order to analyze the effect of the drugs used in DT,
they were evaluated as predictors of the probability of
discontinuation. Each drug was tested separately and, in
the adjusted analysis, all drugs were included with all the
other demographic, clinical and laboratory data in order
to compare their effects.
Statistical analysis
The statistical analysis was performed using the standard
statistical methods for follow-up analysis: Kaplan-Meier
survival analysis was used to assess probability of inter-
ruption; adjusted and unadjusted Cox proportional haz-
ard model was used in order to evaluate the predictors
of treatment interruption, including each of the drugs
used in DT among the other variables.
Results
Descriptive results
Overall, 376 patients were included in the analysis.
The general characteristics of the patients are reported
in Table 1. As shown, patients were generally strongly
pre-treated both with a median long time in ART and a
median high number of previous regimens by patient.
DRV/r was the most used drug among PI/r and RAL
among second drugs, so that the combination including
DRV/r and RAL was the most frequently used (122 pa-
tients, 32.5 %). Among DRV/r treated patients, the dose
of DRV used was available for 207 patients: 162 (72.9 %)
were treated with 800 mg once daily (OD) and 56
(27.1 %) with 600 mg twice daily (BID).
In a median of 508 days of observations (interquartile
range, IQR 198–995), 77 patients (20.5 %) discontinued
DT; the reason for discontinuation was virological failure
in 38 patients (10.1 %), toxicity in 35 (9.3 %), low adher-
ence/personal decision in 12 (3.2 %). Reasons for DT
discontinuation by toxicity included gastro-intestinal
symptoms in 7 patients, lipid elevation in 6, non AIDS-
related death in 4 (2 accidents, 2 non-AIDS related
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cancers), bilirubin elevation or liver toxicity in 4 patients
each, kidney or CNS toxicity in 2 patients each, and it
was unrecorded in 6.
The probability of discontinuation estimated by
Kaplan-Meier survival analysis at one, three and five
years is reported in Table 2. As shown, the probability of
discontinuation was quite high in the first year of treat-
ment, then increased during follow-up but at a slower
rate. Discontinuation by virological failure was more fre-
quent than by toxicity in long term observation.
Study drugs and overall risk of discontinuation
Unadjusted and adjusted assessment for DT discontinu-
ation using Cox proportional hazard model is reported
in Table 3. As shown, at the unadjusted analysis, having
less than 200 CD4 cells/μL at baseline and a higher
number of previous regimens were significantly associ-
ated with a higher risk of treatment discontinuation;
among drugs, only DRV/r use in DT was associated with
a lower risk of discontinuation. In the adjusted model,
among PI/s, ATV/r and DRV/r were associated with
higher risk of discontinuation and, among second drugs,
only RAL came close to a significant association with a
lower risk of discontinuation (p = 0.056). Low CD4 cell
count at baseline and higher number of previous regi-
mens remained significantly associated to the outcome
while a longer time on cART was associated with lower
risk of discontinuation. The adjusted hazard ratio (HR)
for DT discontinuation are also graphically shown in
Fig. 1 (for PI/r) and Fig. 2 (for the second drug).
In a further adjusted model who evaluated the effect
of DRV/r at two different doses, both were significantly
associated with reduced risk of discontinuation (HR
0.16, 95 % CI 0.05–0.58, p = 0.005 for 600 mg BID; HR
0.16, 95 % CI 0.05–0.47, p = 0.001 for 800 mg OD).
Study drugs and risk of discontinuation by secondary
end-points
None of the factors analyzed was significantly associated
with DT discontinuation by virological failure in ad-
justed analysis; however, ATV/r (HR 0.17, 95 % CI 0.03–
1.10, p = 0.065) and DRV/r use (HR 0.22, 95 % CI 0.05–
1.12, p = 0.068) were marginally associated with lower
risk of failure.
A lower risk of discontinuation due to toxicity was as-
sociated to RAL (HR 0.17, 95 % CI 0.04–0.67, p = 0.011)
and 3TC use (HR 0.14, 95 % CI 0.02–1.00, p = 0.05) as
well as to longer duration of cART (HR 0.93, 95 % CI
0.83–0.99, p = 0025).
Finally, DRV/r (HR 0.06, 95 % CI 0.01–0.79, p = 0.032),
RAL (HR 0.09, 95 % CI 0.1–0.79, p = 0.029) and ETR use
(HR 0.09, 95 % CI 0.01–0.89, p = 0.039) were associated
with lower risk of discontinuation for inadequate adher-
ence or patient decision.
Among 35 patients failing DT, 12 failed with HIV-
RNA <1000 mc/ml, resistance at failure test was avail-
able for 18 patients (51.4 %) and, for 5 patients who
failed RAL plus DRV/r regimen, also resistance test for
integrase section of genome. One major mutation for
protease (M46L) and one mutation for reverse tran-
scriptase (M184V), probably due to re-emergence of
NRTI resistance after failure, were detected. Both were
found in two patients failing RAL plus DRV/r combin-
ation, while no integrase mutation was found.
Discussion
The possibility to combine drugs with a high genetic
barrier as PI/r to second drugs with different resistance
Table 1 General characteristics of 376 patients with
undetectable HIV-RNA switching to dual therapy
N (%) Median (IQ range)
Male gender 286 (76.1)
Age 50 (45–55)
Non-Italian origin 38 (10.1)
Years on cART 13 (7–16)
IDU as risk factor 98 (26.1)
AIDS diagnosis 127 (33.8)
N. of prev. regimens 5 (3–9)
CD4+ nadir 123 (46–243)
Baseline CD4+ count 534 (341–701)
HCV co-infection 123 (32.7)
Prev. GRT for VF 238 (63.3)
Switch to PI/r
ATV/r 69 (18.4)
DRV/r 237 (63.0)
LPV/r 70 (18.6)
Switch to second drug
ETR 62 (16.5)
RAL 202 (53.7)
MVC 65 (17.3)
3TC 23 (6.1)
TDF 24 (6.4)
Abbreviations: cART combined antiretroviral therapy, IDU injecting drug use,
HCV hepatitis C virus, GRT genotypic resistance test, VF virological failure, PI/rit
ritonavir-boosted protease inhibitor, ATV/r atazanavir/ritonavir, DRV/r daruna-
vir/ritonavir, LPV/r lopinavir/ritonavir, ETR etravirine, RAL raltegravir, MVC mara-
viroc, 3TC lamivudine, TDF tenofovir
Table 2 Estimated probability of dual therapy discontinuation
by cause (Kaplan-Meier survival analysis)
1 year 3 years 5 years
Overall 13.3 % 26.5 % 36.2 %
Virological failure 5.4 % 14.2 % 21.7 %
Toxicity 7.5 % 13.5 % 13.5 %
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profiles was demonstrated to be effective in pretreated
HIV patients who failed other regimens [23, 24]. Favorable
results were also observed in cART-experienced patients
switched to DT after virological suppression with the aim
of limiting short and long term NRTI-related toxicity. Not
all PI/r were equally effective in DT regimens and their
combination with different second drugs had various re-
sults in term of efficacy, safety and durability.
However, several studies have already shown not so fa-
vorable results of different DT regimens in first line: the
MODERN study, which evaluated the association of
DRV/r with MVC [10] and NEAT study [11], showed
about 17 % of virologic failures as well as development
of integrase resistance mutations in naïve patients
with high baseline viral load failing first-line DT with
DRV/r and RAL. Otherwise, the GARDEL study, also
Table 3 Unadjusted and adjusted association with dual therapy discontinuation by any cause (Cox proportional Hazard Model)
Unadjusted HR (95 % CI) Adjusted HR (95 % CI) P value
Male gender 1.08 (0.63–1.86) 1.12 (0.65–1.92) n.s.
Age (by year) 1.09 (0.98–1.02) 1.00 (0.97–1.03) n.s.
Non-Italian origin 0.45 (0.17–1.24) 0.43 (0.15–1.24) n.s.
Years on cART (each) 0.97 (0.94–1.01) 0.94 (0.89–1.00) 0.033
IDU as risk factor 1.02 (0.93–1.12) 1.01 (0.91–1.11) n.s.
AIDS diagnosis 1.19 (0.75–1.89) 0.84 (0.49–1.44) n.s.
No. of previous regimens (per each one more) 1.04 (1.00–1.09) 1.10 (1.01–1.13) 0.027
CD4 nadir (by 50) 1.37 (0.84–2.21) 1.43 (0.81–2.52) n.s.
<200 /mmc Baseline CD4 count 2.07 (1.19–3.60) 2.18 (1.18–4.03) 0.013
HCV coinfection 0.99 (0.61–1.60) 1.26 (0.75–2.11) n.s.
Previous virological failure 0.89 (0.55–1.42) 1.14 (0.95–1.38) n.s.
Switch to (PI/r)
ATV/r 0.79 (0.41–1.49) 0.29 (0.09–0.99) 0.049
DRV/r 0.61 (0.39–0.96) 0.21 (0.07–0.63) 0.005
LPV/r 2.06 (1.25–3.42) 0.46 (0.14–1.50) n.s.
Switch to (Second Drug)
ETR 1.41 (0.83–2.40) 0.62 (0.23–1.68) n.s.
RAL 0.67 (0.43–1.05) 0.37 (0.13–1.04) n.s.
MVC 0.74 (0.34–1.62) 0.49 (0.15–1.62) n.s.
3TC 1.66 (0.62–3.84) 0.65 (0.18–2.39) n.s.
TDF 1.39 (0.67–2.91) 0.59 (0.18–1.93) n.s.
Fig. 1 Adjusted HR at Cox Proportional Hazard Model for Dual-Therapy Discontinuation: PI/r
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performed in first-line therapy, proved to be effective
in naïve patients [22].
In contrast, induction-maintenance strategy, with sim-
plification to a DT in patients with optimal virological
response, showed more promising results [13, 16].
The present study offers the advantage of evaluating
the results of cART simplification to DT in clinical prac-
tice with a long follow-up, since up to 80 % of patients
remained in DT for a median of 73 weeks.
In our sample, DRV/r was the most frequently used
PI/r, followed by LPV/r and ATV/r. Among the second
drugs, RAL was the most commonly used followed by
MVC and ETR. 3TC and TDF were used in few patients
but significant differences in efficacy and safety were
observed.
DRV/r in association with MCV, ETR or RAL showed
positive results in recent pilot and cohort study [25, 26],
while, the association of DRV/r with MVC showed
disappointing results in randomized clinical trials [10,
27]. The use of DRV/r in combination with RAL was
the most frequently DT used in our sample (one
third of patients) as also observed in other non-
randomized setting [24].
In our sample, RAL and 3TC as second drug showed
the best safety profile and lower discontinuation rates,
RAL is associated with lower toxicity, but in association
with LPV/r showed less safe metabolic profile, in par-
ticular with the development of abnormal triglycerides
level [16, 17].
In our analysis, the use of ATV/r and DRV/r were
associated with a lower risk of discontinuation for
virological failure, with low number of virological fail-
ure generally observed. Despite the efficacy of ATV/r
used in MT or in combination with RAL in naïve
and switched patients was shown to be disappointing
[28–30], the use of the ATV/r has been shown to be
non-inferior to triple therapy in randomized clinical
trials, if associated with 3TC that offers better safety
profile [13, 14].
DRV/r based DT was not associated with higher inter-
ruption by all causes neither combining nor distinguish-
ing the two different doses of the drug in this study.
Previous data demonstrated higher risk of virological
failure associated with the use of DRV/r 800 OD vs 600
BID [26]. Currently, the DRV/r 800 OD schedule is con-
sidered as preferable and cost-effective [31].
Among second drugs, RAL has proven to be safer
when compared with all other second drugs included in
our analysis. Indeed, 20.5 % of discontinuation rate was
observed in patients with low baseline CD4 cell count
and this parameter was independently associated with a
higher risk of discontinuation by all causes. In literature,
RAL was associated to a high risk of virologic failure in
case of lower baseline CD4 cell count [11] and of higher
baseline viral load [8]. Finally, the use of ETR as second
drugs could also be valid options in combination with
PI/r, as already observed in several studies [15, 19].
Although the selection of patients included and data
collection were accurate, our study may have several
limitations. The study lacks of a control group as it was
designed to compare the performance of single drugs
used in DT. Moreover, the choice of including fully sup-
pressed patients at DT initiation, excluding patients with
previous virological failure to drugs used in DT, could
overcome the absence of adherence data, not available in
the study. Finally, data on changes of laboratory values
are not presented as toxicity was evaluated if cause of
discontinuation.
Conclusions
Our analysis suggest that PI/r-based DT can be a useful
switch strategy in HIV-infected patients with effective
virological control overtime. Dual regimens should be
used with caution in patients with low baseline CD4 cell
Fig. 2 Adjusted HR at Cox Proportional Hazard Model for Dual-Therapy Discontinuation: Second Drug
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count and high number of drugs in their history. Among
PI/r, DRV appeared as the best option, followed by
ATV/r, both associated with low probability of discon-
tinuation; however, DRV/r appeared also to be the best
tolerated. Among second drugs, RAL, due to its high
tolerability, is related to the lowest risk of treatment
discontinuation.
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